You are here

  • Home
  • Archive
  • Volume 78, Issue 10
  • Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre

Article Text

Article menu
Download PDFPDF
Letter
Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre
  1. Hanxiao You1,
  2. Guizhi Zhang2,
  3. Qian Wang1,
  4. Shangzhu Zhang1,
  5. Jiuliang Zhao1,
  6. Xinping Tian1,
  7. Hongbin Li2,
  8. Mengtao Li1,
  9. Xiaofeng Zeng1
  1. 1 Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center on Rheumatology, Ministry of Science & Technology, Beijing, China
  2. 2 Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical College, Hohhot, China
  1. Correspondence to Dr Mengtao Li, Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center on Rheumatology, Ministry of Science & Technology, Beijing 100730, China; mengtao.li{at}cstar.org.cn; Dr Xiaofeng Zeng, Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center on Rheumatology, Ministry of Science & Technology, Beijing 100730, China; zengxfpumc{at}163.com

https://doi.org/10.1136/annrheumdis-2019-215455

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Janus kinases (JAKs) are intracellular tyrosine kinases which play a key role in the signal pathways of many cytokines, such as type l interferons (IFNs), interleukin-6 (IL-6), IL-12 and IL-23.1 All these cytokines participate in the pathogenesis of systemic lupus erythematosus (SLE). Hence, inhibition of JAK signals has provided an attractive therapeutic option in SLE. Tofacitinib can inhibit JAK1/JAK3 and has been proved effective in rheumatoid arthritis (RA),2 psoriatic arthritis and ulcerative colitis. Evidence in murine lupus have shown that tofacitinib can decrease the levels of anti-double-stranded (ds) DNA and proteinuria, remit nephritis and skin rash.3 A case report proved that tofacitinib could decrease anti-dsDNA levels in inactive SLE complicated by RA.4 A phase II randomised controlled trial reported modest efficacy of a JAK1/2 inhibitor, baricitinib, in ameliorating lupus arthritis.5

    To better understand the efficacy of tofacitinib in SLE, we describe, to our knowledge for the first time, the efficacy of tofacitinib 5 mg …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • HY and GZ contributed equally.

    • Funding This work was supported by the Chinese National Key Research R&D Program (grant number 2017YFC0907601, 2017YFC0907602, 2017YFC0907603, 2008BAI59B02) and the Chinese National High Technology Research and Development Program, Ministry of Science and Technology (grant number2012AA02A513).

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Ethics approval Approved by the Ethics Committee of Peking Union Medical College Hospital.

    • Provenance and peer review Not commissioned; externally peer reviewed.